20-F: Radiopharm Narrows Losses, Advances Clinical Pipeline

Radiopharm Theranostics reported a reduced comprehensive loss in fiscal 2025, driven by increased revenue and R&D tax incentives, while advancing multiple radiopharmaceutical drug candidates through clinical trials.

Summary

• Radiopharm Theranostics Limited reported a total comprehensive loss of A$37.88 million for the fiscal year ended June 30, 2025, a significant improvement from A$47.75 million in fiscal 2024.
• Revenue from contracts with customers increased substantially to A$3.63 million in fiscal 2025, up from A$0.29 million in fiscal 2024, primarily due to increased revenue from Lantheus related to the DUNP19 trial.
• Other income surged to A$10.26 million in fiscal 2025 from A$1.34 million in fiscal 2024, largely due to the recognition of A$9.37 million in R&D tax incentives from the Australian government, including A$3.59 million relating to prior years' rebates.
• Net cash used in operating activities increased to A$36.65 million in fiscal 2025 from A$22.98 million in fiscal 2024, reflecting increased payments to suppliers and employees for clinical trial activities.
• The company ended fiscal 2025 with A$29.12 million in cash and cash equivalents, anticipating this to be sufficient to fund operations through fiscal 2026.
• Multiple drug candidates are progressing: RAD202 (HER2 breast/gastric cancer) started Phase I in Australia in H2 2024, with Phase II in the US expected in H2 2026; RAD204 (non-small cell lung cancer) started Phase I in Australia in January 2024, with Phase II in the US expected by Q4 2026.
• RAD101 (Pivalate Brain Metastasis Diagnostic) received FDA IND approval for Phase IIb in July 2024, with completion expected by Q1 2026, and Phase III planned for H2 2026.
• RAD301 (Av6-Integrin Pancreatic Diagnostic) received FDA IND approval in October 2023 and started Phase I in February 2024; Phase II is expected by H1 2026.
• Radiopharm Ventures LLC, a joint venture with MD Anderson, received IND approval in July 2025 for its B7H3 mAb therapeutic candidate, with a Phase I clinical trial planned by the end of 2025.
• The company acquired Pharma15 Corporation in March 2023, focusing on next-generation therapeutic radiopharmaceuticals for prostate cancer.
• Lantheus Omega, LLC made significant equity investments, purchasing 149.6 million ordinary shares for A$7.5 million in June 2024 and 133 million ordinary shares for US$5.0 million in January 2025.
• A strategic development services contract with Lantheus was established in October and December 2024, where Radiopharm leads Australian clinical development efforts for innovative radiopharmaceuticals, with Lantheus covering all associated costs and providing up to US$2 million in milestone payments.
• The company transferred two early pre-clinical assets (TROP2 and DUNP19) to Lantheus Omega in June 2024 for A$3 million.
• Radiopharm holds 34 patents and has a global intellectual property strategy, with key claims in Patent Cooperation Treaty applications confirmed as novel and inventive.
• The company is subject to extensive regulation by authorities such as the FDA, EMA, and TGA, with drug approval processes requiring substantial time and resources.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to incur significant losses and increase its cash burn from operations, the substantial increase in revenue, significant R&D tax incentives, and strategic investments from a major industry player like Lantheus are strong positives. The progression of multiple drug candidates into later clinical phases and IND approvals also indicates good operational progress. However, the continued reliance on capital raises and the inherent risks of clinical-stage biotech temper the overall sentiment.

Positives

• Total comprehensive loss decreased by A$9.87 million, from A$47.75 million in fiscal 2024 to A$37.88 million in fiscal 2025.
• Revenue from contracts with customers increased significantly by A$3.33 million, from A$299,228 in fiscal 2024 to A$3,633,422 in fiscal 2025, driven by the Lantheus DUNP19 trial.
• Other income increased by A$8.91 million, from A$1.34 million in fiscal 2024 to A$10.26 million in fiscal 2025, largely due to R&D tax incentives.
• Received FDA IND approval for RAD101 (brain metastases) in July 2024, allowing progression to Phase IIb.
• Received FDA IND approval for Radiopharm Ventures' B7H3 mAb therapeutic candidate in July 2025, with Phase I planned by end of 2025.
• RAD301 (pancreatic cancer) received Orphan Drug Designation by the FDA in May 2023 and started Phase I in February 2024.
• Strategic equity investments from Lantheus Omega, LLC totaling A$7.5 million (June 2024) and US$5.0 million (January 2025) strengthen the capital base.
• Established a strategic development services contract with Lantheus, where Lantheus covers clinical development costs in Australia and provides milestone payments up to US$2 million.
• Completed the assignment of DUNP19 assets to Lantheus Holdings, generating A$3 million in proceeds.
• Maintained a strong intellectual property portfolio with 34 patents, and key claims in PCT applications confirmed as novel and inventive.
• Management believes current cash and cash equivalents of A$29.12 million are sufficient to fund operations through fiscal 2026.

Negatives

• Continued to incur significant operating losses (A$37.88 million in fiscal 2025) and negative cash flows from operating activities (A$36.65 million in fiscal 2025).
• Research and development expenses increased by A$4.43 million, from A$23.09 million in fiscal 2024 to A$27.52 million in fiscal 2025, indicating a high burn rate.
• General and administrative expenses increased by A$1.60 million, from A$13.04 million in fiscal 2024 to A$14.64 million in fiscal 2025, primarily due to employee benefits and legal expenses.
• The company currently has no source of product revenue and expects it to be several years before any drug candidates are approved and commercialized.
• Will require substantial additional financing to achieve long-term goals and complete drug candidate development, with no guarantee of availability on acceptable terms.
• The clinical data gathered outside the United States for RAD101, RAD201, and RAD204 Phase I/II trials may not be accepted by the FDA, potentially requiring additional costly trials in the US.
• Postponed further development of RAD201 (Nano-mAb HER-2 Breast Diagnostic) to prioritize therapeutic assets.
• Contingent liabilities related to milestone payments under license agreements remain significant, totaling A$32.10 million as of June 30, 2025.
• The company's ADS holders are not treated as shareholders and do not have the same voting or dividend rights as ordinary shareholders.

Risks

• History of operating losses and may not achieve or maintain profitability in the future.
• Research and development activities could be adversely impacted by insufficient funding and revenue.
• Currently has no source of product revenue and may never become profitable.
• Will require additional financing and may be unable to raise sufficient capital, materially impacting R&D or commercialization.
• Difficulty enrolling patients in clinical trials or patient discontinuation could delay or prevent trials and increase costs.
• Failure to implement business strategy could negatively impact business, financial condition, and results of operations.
• Positive preclinical results are not necessarily predictive of clinical trial success.
• Ongoing and future clinical trials may not show sufficient safety and efficacy for regulatory approvals.
• Failure to obtain necessary regulatory approvals will prevent commercialization of drug candidates.
• Even with regulatory approval, drug candidates may face development and regulatory difficulties delaying or impairing future sales.
• Limited manufacturing experience and dependence on third-party contractors for manufacturing and supply.
• Dependence on collaboration and strategic alliances with third-party partners exposes the company to risks related to their business and operational conditions.
• Inability to retain key management personnel and cultivate academic/scientific collaborations could jeopardize R&D efforts.
• Difficulties in managing growth could negatively impact operations.
• Future potential sales may suffer if drug candidates are not accepted by physicians, patients, and the medical community.
• Faces intense competition from entities developing drug candidates for target disease indications.
• Healthcare insurers and other organizations may not pay for drug candidates or impose reimbursement limits.
• Exposure to product liability claims could harm the business.
• Outbreak of a pandemic could adversely impact business, including non-clinical studies and clinical trials.
• Success depends on the ability to protect intellectual property and proprietary technology.
• Intellectual property rights of third parties could adversely affect the ability to commercialize drug candidates, potentially requiring litigation or licenses.
• Reliance on third parties requires sharing trade secrets, increasing risk of discovery or misappropriation.
• Obtaining and maintaining patent protection depends on compliance with various procedural requirements, and non-compliance could reduce or eliminate protection.
• May become involved in lawsuits to protect and defend patents or other intellectual property, which could be expensive, time-consuming, and unsuccessful.
• Confidentiality and invention assignment agreements may not adequately prevent disclosure of trade secrets.
• Intellectual property rights do not address all potential threats to competitive advantage.
• May face difficulties protecting intellectual property in certain jurisdictions, diminishing its value.
• Changes in patent law could diminish the value of patents in general.
• Price controls may be imposed in non-U.S. markets, negatively affecting future profitability.
• The trading price of ADSs may be volatile, and purchasers could incur substantial losses.
• If classified as a Passive Foreign Investment Company (PFIC), U.S. shareholders would be subject to adverse tax rules.
• Requirements of being a public company may strain resources and divert management's attention.
• Could become subject to auditor attestation requirement under Sarbanes-Oxley Act, imposing significant cost and administrative burden.
• Issuance of additional ordinary shares in connection with financings, acquisitions, or investments will dilute other ADS holders.
• ASX Listing Rule 7.1 may limit capital raisings without shareholder approval.
• Subject to risks associated with currency fluctuations, impacting results of operations.
• ADS holders are not shareholders and do not have shareholder rights.
• ADS holders do not have the same rights to receive dividends or other distributions as shareholders.
• Circumstances may make it unlawful or impractical to make distributions to ADS holders.
• ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement.
• Exclusive jurisdiction and arbitration provisions in the deposit agreement may discourage claims or limit ability to bring a claim.
• Australian takeover laws may discourage takeover offers or acquisition of large numbers of shares.
• Holders of ordinary shares or ADSs may have difficulty effecting service of process or enforcing judgments obtained in the United States.
• As a foreign private issuer, may follow home country corporate governance practices instead of certain Nasdaq requirements.
• As a foreign private issuer, exempt from a number of U.S. securities laws and subject to lower disclosure requirements.
• Loss of foreign private issuer status could result in significant additional cost.
• U.S. investors may have difficulty enforcing civil liabilities against the company, directors, or senior management.
• Quorum requirements and voting procedures may not protect shareholders' interests.

Future Outlook

The company expects to continue incurring losses and cash outflows for the foreseeable future as it invests heavily in research and development for its clinical pipeline. It anticipates requiring substantial additional funds to achieve long-term goals and complete drug candidate development. The company plans to pursue FDA approval for all product candidates and seek marketing approval in other regions like the EU, UK, China, Japan, Australia, and Canada. Strategic partnerships and collaborations will continue to be sought to advance product candidates and explore new opportunities.

Management Comments

• Management has assessed the clinical trial activities and expenses to determine which activities are likely to be eligible under the R&D tax incentive regulations.
• Management has assessed the Pharma15 asset at each reporting period to determine if it is ready for use, concluding it is not yet ready as there are currently no patents for the asset.
• The group's ongoing viability and ability to continue as a going concern depends on its capacity to meet debts and commitments as they fall due, and based on current budget forecast assumptions, the group is in a position to meet future commitments and progress R&D programs for at least the next 12 months.
• The group has the ability to employ cash management strategies such as delaying or reducing some operating activities and raise further capital subject to maintaining an active listing on the NASDAQ exchange as well as compliance with the group's obligations under ASX Listing Rule 7.1.
• The group's track record of successful capital raises provides confidence in their ability to secure funding if required.

Industry Context

Radiopharm Theranostics operates in the highly competitive and capital-intensive radiopharmaceutical and precision oncology sector. The company's strategy to develop theranostic radiopharmaceuticals for both diagnostic and therapeutic applications aligns with a growing industry focus on targeted radiotherapy and high linear energy transfer therapies. The market for targeted indications is estimated to be over US$6 billion, indicating significant potential. Key competitors like AAA/Novartis, Telix, Clarity, Point Bio, and RayzeBio are also active in developing radioligand therapies and imaging agents, with some already having commercialized products or advanced clinical pipelines. Radiopharm's focus on novel molecular targets (e.g., KLK3, AvB6, PTPmu) and nanobody platforms aims to differentiate it from existing and emerging treatments, which often rely on different small molecules or monoclonal antibodies. The strategic partnerships with major players like Lantheus and leading research institutions like MD Anderson are crucial for a clinical-stage company to navigate the complex development and regulatory landscape and compete effectively.

Comparison to Industry Standards

• Compared to AAA/Novartis, which has commercialized radioligand therapies like Lutathera and Pluvicto, Radiopharm is still in earlier clinical stages, focusing on developing its pipeline towards regulatory approval.
• Telix, with FDA and TGA approved Illuccix for prostate cancer imaging, represents a competitor with established market presence in diagnostic radiopharmaceuticals, while Radiopharm's assets are still undergoing trials.
• Clarity's focus on copper isotopes for therapeutics and imaging for various cancers highlights a different isotopic approach compared to Radiopharm's use of Lu177, I-131, At-211, and Ga68.
• The acquisition of Point Bio by Eli Lilly for $1.4 billion and RayzeBio by BMS for $4.1 billion in 2023 demonstrates significant M&A activity and investor interest in the radiopharmaceutical space, suggesting potential for Radiopharm's assets if they achieve clinical success.
• Radiopharm's strategy to develop theranostic radiopharmaceuticals that combine diagnosis and treatment is consistent with a key trend in nuclear medicine, aiming to address shortcomings of traditional chemotherapy and external beam radiation therapy by reducing off-target effects.

Management Changes

Corporate Governance

Legal Proceedings

• Not involved in any legal or arbitration proceedings that could have a material adverse impact on financial position or profitability.
• Not currently involved in any governmental proceedings, and none are contemplated.

Related Party Transactions

• In fiscal 2025, the Acclime Group, where Phillip Hains (CFO and Director) is a Director, invoiced Radiopharm A$415,909 for professional services (financial reporting, capital management, company secretarial, accounting, bookkeeping, and payroll activities).
• In fiscal 2024, the Acclime Group invoiced Radiopharm A$605,390 for similar professional services.
• In fiscal 2024, Paul Hopper (Executive Chairman) and Phillip Hains loaned A$2.2 million to Radiopharm to support operations, which was fully repaid in June 2024. No such loans in fiscal 2025.
• In fiscal 2021, Paul Hopper loaned A$69,000 to Radiopharm, which was repaid in fiscal 2022.

Stakeholder Impact

• Shareholders: Dilution risk from future equity financings and share-based milestone payments. Potential for long-term value creation if clinical pipeline succeeds. ADS holders have different rights than ordinary shareholders.
• Employees: Increased employee benefits expenses reflect growth in headcount, particularly in R&D. Share-based payment plans aim to incentivize and retain key talent.
• Customers: Development of novel radiopharmaceutical products aims to address high unmet medical needs in oncology, potentially offering more effective diagnostic and therapeutic options.
• Suppliers/Contractors: Continued reliance on third-party manufacturers and clinical research organizations for R&D and manufacturing, indicating ongoing business for these partners.
• Creditors: The company's ongoing losses and need for future financing present a risk, though management expresses confidence in meeting commitments and securing funding.

Next Steps

• Complete Phase I of RAD202 (HER2 breast/gastric cancer) in Australia by H1 2026.
• Seek IND approval from the FDA to start Phase II trial with RAD202 after completion of Phase I.
• Start Phase II of RAD202 in the United States in H2 2026, aiming for completion by early 2028.
• Complete Phase I of RAD204 (non-small cell lung cancer) in Australia by H2 2026.
• Seek IND approval from the FDA to start Phase II trial with RAD204 after completion of Phase I.
• Start Phase II for RAD204 in the United States by Q4 2026, aiming for completion by end of 2027.
• Complete Phase IIb for RAD101 (brain metastases) in the United States by Q1 2026.
• Plan Phase III for RAD101 in the United States to start in H2 2026, aiming for completion by early 2028.
• Start Phase II for RAD301 (pancreatic cancer) in the United States by H1 2026, aiming for completion by H1 2027.
• Start Phase I clinical trial for RAD302 (pancreatic, head-neck, lung cancer) in the United States in 2026.
• Request Ethics Committee approval for RAD402 (prostate cancer) Phase I therapeutic trial in Australia by end of 2025.
• Submit IND to FDA for RAD402 Phase II in 2027.
• Initiate Phase I clinical trial for Radiopharm Ventures' B7H3 mAb therapeutic candidate in the United States by end of 2025.
• Continue to seek additional funding through public or private financings and/or licensing arrangements.
• Maintain and expand current partnerships with nuclear medicine suppliers to ensure isotope supply.
• Be opportunistic in seeking other opportunities to expand clinical assets.
• Pursue FDA approval of all product candidates and marketing approval in other regions (EU, UK, China, Japan, Australia, Canada).
• Continue to seek strategic partnerships and collaborations for product development.
• Maintain a strong global intellectual property portfolio, pursuing patent protection in key markets.

Key Dates

Recommendation

Radiopharm Theranostics is a clinical-stage biopharmaceutical company with a promising pipeline of radiopharmaceutical drug candidates targeting various cancers. The significant reduction in total comprehensive loss and increased revenue in fiscal 2025 are positive indicators of operational improvement and successful execution of strategic partnerships, particularly with Lantheus. The progression of multiple assets into Phase I/II trials and recent IND approvals demonstrate tangible R&D advancement. However, the company continues to incur substantial operating losses and has an increasing cash burn from operating activities, necessitating further capital raises. The inherent risks associated with clinical development, regulatory approvals, manufacturing, and market acceptance for novel therapies remain high. While strategic partnerships and R&D tax incentives provide some financial cushion, the long path to commercialization and profitability means the stock carries considerable risk. A 'hold' recommendation is appropriate for investors who are already exposed to the stock and believe in the long-term potential of its pipeline, acknowledging the significant capital requirements and execution risks ahead. New investors should approach with caution, given the early stage of development and reliance on future financing.

Keywords

Radiopharmaceutical, Theranostics, Oncology, Cancer Therapy, Diagnostic Imaging, Clinical Trials, Drug Development, Biotechnology, HER2, PDL1, Brain Metastases, Pancreatic Cancer, Prostate Cancer, Glioblastoma, Intellectual Property, SEC Filing, ASX, Nasdaq, R&D Tax Incentive, Lantheus